Lablol 100mg Injection (Labetalol) 20ml

Lablol 100mg Injection (Labetalol) 20ml — Complete Clinical and Patient Information Guide

Product Overview

Lablol 100mg Injection (Labetalol) 20ml contains Labetalol Hydrochloride 100mg/20ml IV as its active pharmaceutical ingredient, belonging to the combined alpha-1 and non-selective beta-adrenoceptor antagonist — intravenous formulation for hypertensive emergencies. It is clinically indicated for hypertensive emergency (BP ≥180/120mmHg with target-organ damage); hypertensive urgency requiring rapid parenteral blood pressure reduction; eclampsia and severe pre-eclampsia; aortic dissection (acute); post-operative hypertension. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established cardiovascular clinical guidelines.

Lablol 100mg Injection provides labetalol 100mg/20ml IV — the preferred parenteral antihypertensive for hypertensive emergencies requiring rapid blood pressure reduction without reflex tachycardia, with particular advantage in pregnancy-related hypertension and eclampsia.

About Lablol 100mg Injection and Its Active Ingredient

Labetalol Hydrochloride 100mg/20ml IV is the pharmacologically active compound in Lablol 100mg Injection. Cardiovascular medications are among the most safety-critical drugs prescribed — interactions with other heart medications, anticoagulants, and antihypertensives can have life-threatening consequences, and abrupt discontinuation of certain cardiac drugs (beta-blockers, anticoagulants) without medical guidance can precipitate dangerous rebound phenomena. All cardiovascular pharmacotherapy decisions require specialist or physician oversight, with regular monitoring and dose optimisation based on clinical response, ECG findings, blood pressure recordings, and relevant biochemical parameters.

Mechanism of Action

Labetalol is a unique combined alpha-1 and non-selective beta-adrenoceptor blocker with an oral alpha:beta blocking ratio of approximately 1:3 and an IV alpha:beta ratio of approximately 1:7 (reflecting the formulation-dependent pharmacodynamic profile). The combined alpha-1 and beta blockade produces vasodilation (alpha-1 blockade reduces peripheral vascular resistance) simultaneously with reduced cardiac rate and output (beta-1 blockade) and prevents reflex tachycardia (beta-1 blockade prevents the compensatory heart rate increase that would otherwise follow pure alpha-blockade). This combined action is particularly valuable in hypertensive emergencies: IV labetalol produces rapid blood pressure reduction without reflex tachycardia, without compromising cerebral perfusion (beta-mediated cerebrovascular autoregulation is partially preserved), and with predictable dose-response in titrated infusion — making it the preferred parenteral antihypertensive for hypertensive emergency including eclampsia, aortic dissection, and post-operative hypertension.

A clear understanding of the pharmacological mechanism helps explain the clinical requirements: why timing, dose titration, monitoring, drug interactions, and contraindications exist. Healthcare providers use mechanistic knowledge to individualise therapy, anticipate interactions, and monitor for treatment response and toxicity.

Clinical Indications

Lablol 100mg Injection (Labetalol) 20ml is clinically indicated for:

• Primary indication: hypertensive emergency (BP ≥180/120mmHg with target-organ damage); hypertensive urgency requiring rapid parenteral blood pressure reduction; eclampsia and severe pre-eclampsia; aortic dissection (acute); post-operative hypertension
• Specialist assessment required: Cardiovascular drug therapy must be initiated and monitored by a qualified cardiologist, physician, or specialist. Self-diagnosis and self-treatment of cardiac conditions is dangerous and may delay life-saving treatment.

Dosage and Administration

Administered only by trained healthcare professionals in monitored clinical settings (ICU, HDU, emergency department). IV bolus: 20mg over 2 minutes; can repeat 40–80mg every 10 minutes to maximum cumulative 300mg. IV infusion: 1–2mg/min, titrated to response. Continuous BP monitoring required. Position patient supine for at least 3 hours post-injection (orthostatic hypotension risk).

Never adjust the dose or stop cardiovascular medications without consulting your prescribing physician. Abrupt withdrawal of beta-blockers, anticoagulants, and anti-anginal drugs can cause dangerous rebound phenomena including angina exacerbation, myocardial infarction, and thromboembolic events.

Who Should Use Lablol 100mg Injection

Lablol 100mg Injection is indicated for adult patients in whom the relevant cardiovascular condition has been confirmed by clinical assessment and appropriate investigations (ECG, echocardiogram, cardiac biomarkers, blood pressure recording, coagulation studies as applicable) and in whom this specific pharmacological approach has been determined to be clinically appropriate after benefit-risk assessment.

Contraindications

Severe bradycardia or sick sinus syndrome. High-degree AV block (second or third degree) without pacemaker. Severe decompensated heart failure (acute/unstable — stable HFrEF is an indication). Significant bronchospasm or severe asthma (non-selective beta-blockers absolute; cardioselective relatively contraindicated). Significant peripheral arterial disease (relative). Cardiogenic shock. Hypersensitivity. IV labetalol: additional contraindications for hypertensive emergencies — severe asthma/COPD (beta-2 blockade). Avoid in cocaine-induced hypertension (paradoxical BP rise from unopposed alpha stimulation if beta component dominates). Pheochromocytoma (risk of hypertensive crisis without prior alpha-blockade).

Drug Interactions

Halothane anaesthesia: severe bradycardia. Calcium channel blockers (verapamil, diltiazem): additive AV block and myocardial depression. Insulin: masking of hypoglycaemia signs. Cimetidine: increases labetalol bioavailability. Nitroglycerin: additive hypotension.

Cardiovascular drugs have numerous clinically significant, potentially dangerous drug interactions. A comprehensive medication review by a cardiologist or clinical pharmacist is essential before initiating or changing any cardiac medication. Patients must inform all healthcare providers (including dentists, surgeons, and emergency physicians) of all their cardiovascular medications.

Adverse Effects

Common: Fatigue, bradycardia, cold extremities, dizziness, and sleep disturbance (nightmares — particularly with lipophilic agents crossing the BBB like propranolol, metoprolol). Uncommon: Bronchoconstriction (non-selective > cardioselective), sexual dysfunction, depression, and masking of hypoglycaemic symptoms in diabetics. Rare: Severe bradyarrhythmia, AV block, acute heart failure decompensation (with rapid dose escalation in already-compromised heart).

IV-specific: orthostatic hypotension is the most significant practical concern — patients must remain supine for 3 hours after IV labetalol; ambulation before this time risks fainting. Scalp tingling (characteristic and benign). Neonatal bradycardia and hypoglycaemia if used in eclampsia — monitor newborn.

Special Population Considerations

Eclampsia use: Labetalol IV is a first-line treatment for severe hypertension in pregnancy/eclampsia — it provides effective BP reduction while maintaining uteroplacental blood flow, does not cause reflex tachycardia, and is safe for both mother and foetus (unlike many other IV antihypertensives). Supine positioning mandatory: Patients MUST remain horizontal for at least 3 hours after IV labetalol to prevent dangerous orthostatic hypotension. Oral conversion: After IV control, transition to oral antihypertensive therapy is managed by the treating specialist.

Storage and Handling

Store Lablol 100mg Injection at room temperature (15–25°C) in a dry location away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use beyond the printed expiry date. Nitroglycerin preparations require special storage in airtight glass containers away from heat — plastic and light degrade GTN. Enoxaparin: store at room temperature; do not freeze.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next scheduled dose. Never double-dose. Do not stop beta-blockers, anticoagulants, or anti-anginal medications abruptly without medical advice.

Q: Is IV labetalol safe in pregnancy?
A: Yes — IV labetalol is one of the preferred treatments for severe hypertension in pregnancy and eclampsia. Unlike many antihypertensives, labetalol is considered safe in pregnancy and is recommended in multiple international obstetric guidelines as a first-line agent for maternal hypertension. Monitor neonates for bradycardia and hypoglycaemia. Labetalol is avoided before delivery in some protocols — specialist obstetric guidance required.

Evidence Base and Cardiovascular Guidelines

The active ingredient in Lablol 100mg Injection has been evaluated in landmark randomised controlled trials and is supported by major international cardiovascular guidelines including those from the European Society of Cardiology (ESC), American College of Cardiology/American Heart Association (ACC/AHA), American Heart Association, National Institute for Health and Care Excellence (NICE), and relevant national cardiovascular specialist bodies. These guidelines represent evidence-based consensus on optimal pharmacological management of cardiovascular conditions and are regularly updated as new clinical evidence emerges.

Cardiovascular disease management has undergone transformative advances over the past three decades — from the landmark MERIT-HF, CAPRICORN, and EMPHASIS-HF trials establishing guideline-directed medical therapy for heart failure, to the COURAGE trial for stable angina, EINSTEIN for anticoagulation, and ADVANCE-HF for newer agents. Patients benefit most when their individual pharmacotherapy aligns with current evidence-based guidelines.

Patient Counselling Points

• Never stop abruptly: Beta-blockers, anti-anginal drugs, and anticoagulants must never be stopped suddenly without medical guidance — abrupt withdrawal can trigger angina rebound, myocardial infarction, arrhythmia, or thromboembolic events.
• Carry a medication list: All patients on cardiovascular drugs should carry a current medication list for any medical encounter — including surgical, dental, and emergency care. Drug interactions in cardiovascular patients can be life-threatening.
• Regular monitoring: Blood pressure, ECG, renal function, electrolytes (for diuretics), INR (for warfarin), platelet count (for heparins), and cardiac biomarkers as appropriate should be monitored at intervals determined by your cardiologist.
• Lifestyle integration: Pharmacotherapy delivers best results alongside appropriate lifestyle modification: Mediterranean diet, regular aerobic exercise, smoking cessation, moderate alcohol, sodium restriction for hypertension and heart failure.

Cardiovascular Disease Context and Clinical Management Principles

Cardiovascular disease (CVD) remains the leading cause of death globally, responsible for approximately 18 million deaths annually — representing 32% of all global mortality. Coronary artery disease, heart failure, hypertension, stroke, and peripheral arterial disease collectively impose an enormous burden of mortality, morbidity, and reduced quality of life worldwide. The last five decades have witnessed transformative advances in cardiovascular pharmacotherapy — from the introduction of beta-blockers and ACE inhibitors, through the development of statins and thrombolytics, to the current era of guideline-directed medical therapy with proven mortality-reducing agents for heart failure, and novel anticoagulants revolutionising stroke prevention in atrial fibrillation.

Effective cardiovascular disease management requires integration of pharmacological therapy with lifestyle modification (Mediterranean diet, regular aerobic exercise, smoking cessation, alcohol moderation, sodium restriction), risk factor control (blood pressure, lipid management, glycaemic control, weight management), and appropriate interventional or surgical procedures where indicated. Pharmacotherapy alone, without lifestyle integration and risk factor management, provides suboptimal benefit — drugs and lifestyle modification are synergistic, not alternative, approaches.

Hypertension: The Silent Cardiovascular Risk Factor

Hypertension affects approximately 1.28 billion adults worldwide, yet only 21% of hypertensive adults have their blood pressure adequately controlled. Uncontrolled hypertension is the leading modifiable risk factor for stroke, coronary artery disease, heart failure, renal failure, and peripheral arterial disease. The relationship between blood pressure and cardiovascular risk is continuous — even high-normal blood pressure (130–139/85–89 mmHg) carries increased cardiovascular risk compared to optimal levels.

Current international guidelines (ESC/ESH, ACC/AHA, NICE) recommend initial drug therapy for hypertension with one of three evidence-based drug classes: angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); calcium channel blockers (CCBs); or thiazide/thiazide-like diuretics. Most patients with stage 2 hypertension (≥160/100 mmHg) require combination therapy from initial diagnosis. Fixed-dose combination tablets — such as those in this product range — improve adherence and simplify therapy for patients requiring multiple agents.

Angina Pectoris: Management Principles

Stable angina pectoris affects over 110 million people globally and represents myocardial ischaemia occurring predictably with exertion or emotional stress, relieved by rest or sublingual nitroglycerin within minutes. The management goal is threefold: symptom relief, prevention of disease progression and MI, and improvement of quality of life. First-line symptomatic therapy uses beta-blockers and/or calcium channel blockers as rate-limiting or vasodilatory agents; long-acting nitrates or nicorandil are added when first-line therapy is insufficient. For resistant symptoms, trimetazidine or ivabradine (when HR remains elevated) provide additional anti-anginal mechanisms. When pharmacological therapy fails to control symptoms adequately, coronary revascularisation (PCI or CABG) should be considered.

Quality Standards and Evidence Base

The active ingredients in products in this range have been evaluated in landmark randomised controlled trials that form the foundation of evidence-based cardiovascular medicine: MERIT-HF (metoprolol succinate in HFrEF), CAPRICORN and COPERNICUS (carvedilol in post-MI LV dysfunction and HFrEF), BEAUTIFUL (ivabradine in stable CAD), SIGNIFY (ivabradine in stable angina), EINSTEIN (enoxaparin in VTE), EXTRACT-TIMI 25 (enoxaparin in STEMI), and IONA (nicorandil in stable angina). Major cardiovascular guidelines from the ESC, ACC/AHA, and NICE incorporate these drugs into evidence-based treatment algorithms based on the totality of this evidence.

Products are manufactured in compliance with Good Manufacturing Practice (GMP) standards required by national and international pharmaceutical regulatory authorities, ensuring consistent quality, identity, strength, and purity. Patients should always obtain prescription cardiovascular medications from licensed pharmacies with valid prescriptions to ensure receipt of authentic, properly stored, quality-assured products.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed cardiology literature, and established clinical guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified cardiologist, physician, or pharmacist. Cardiovascular drug therapy decisions must be individualised by a licensed healthcare provider with full knowledge of the patient’s cardiac status, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of cardiovascular conditions can be dangerous and life-threatening. Always consult a qualified cardiologist or physician before starting, changing, or stopping any cardiovascular medication.